All lobbying filings

S-3 GROUP

Lobbying for VIATRIS (MYLAN, INC) · Generics and specialty pharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Pennsylvania · House · Senate · $60,000.00 income · posted Apr 17, 2026

Official filing document

Bills named in this filing 5

S 1302
Increasing Transparency in Generic Drug Applications Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 527
Prescription Pricing for the People Act of 2025
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 1041
Affordable Prescriptions for Patients Act

Lobbying activity 2

Health Issues

Issues related to drug pricing; pharmaceutical supply chain; modernization of prescribing information for physicians and pharmacists; Increasing Transparency in Generic Drug Applications, S.1302 and H.R. 1843; Part D Formulary Design and Generic Drug Testing

Issues related to patent policy and reform, including to address patent thickets and FDA/PTO Coordination; S.527 Prescription Pricing for the People Act; S.1096 Preserve Access to Affordable Generics and Biosimilars Act; S.1041 Affordable Prescriptions for Patients Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.